Clinical trials: Glioblastoma
Glioblastoma (GBM)
Efficacy of Zoster Vaccination in Glioblastoma Patients
In modern practice a trimodality treatment has emerged as standard of care for histologically confirmed glioblastoma. We hypothesize that the additional vaccination against herpes zoster, after surgical resection followed by…
- Trial name
- STARGATE (NCT07546669)
- Testing
- Additional vaccination against shingles (herpes zoster), Standard of care treatment without additional vaccination
- Volunteers
- 230 people
- Sponsor
- University Hospital, Essen
Glioblastoma (GBM), Brain Metastasases
A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases
This will be an open-label Phase 0/1 study that will enroll approximately 15 participants, 9 participants with recurrent WHO Grade 4 glioma (rGBM) and 6 participants with brain metastases, who will receive the investigational…
- Trial name
- NCT07268053
- Testing
- Risvutatug rezetecan
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Nader Sanai
Glioblastoma, Low Grade Glioma
Mind-Body Intervention in Glioma Couples
This trial studies how well a couple-based mind body program works in improving spiritual, psychosocial, and physical quality of life in patients with high or low grade glioma or tumors that have spread to the brain and their…
- Conditions
- Glioblastoma, Low Grade Glioma, Malignant Glioma, Metastatic Malignant Neoplasm in the Brain
- Trial name
- NCT03244995
- Testing
- Mind-Body Intervention Procedure, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
HPV-Positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation
This Phase 2a/2 study evaluates the safety, tolerability, and efficacy of neoadjuvant and adjuvant NAI, hAd5-HPV vaccine (IBRX-042), and nab-paclitaxel in participants with locally advanced HPV-positive oropharyngeal squamous…
- Conditions
- HPV-Positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Head and Neck Cancer
- Trial name
- NCT07628062
- Testing
- Nogapendekin Alfa Inbakicept (NAI), hAd5-HPV Vaccine (IBRX-042), Nab-Paclitaxel
- Volunteers
- 70 people
- Sponsor
- ImmunityBio, Inc.
Adult Brain Tumors
Erlotinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well erlotinib works in treating patients with recurrent glioblastoma…
- Trial name
- NCT00387894
- Testing
- erlotinib hydrochloride
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Michael Prados
Glioblastoma Multiforme, Glioblastoma
Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)
This will be a prospective, open-label, single-arm pilot study to investigate the safety and efficacy of Bevacizumab (BEV) in combination with microbubble (MB)-mediated FUS in patients with recurrent GBM.
- Conditions
- Glioblastoma Multiforme, Glioblastoma, Glioma, Brain Tumor
- Trial name
- NCT06329570
- Testing
- NaviFUS System, Lumason, Bevacizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- NaviFUS Corporation
Glioblastoma
Imaging and Biological Markers for Prediction and Identification of Glioblastoma Pseudoprogression: a Prospective Study.
The goal of this interventional study is the development and validation of imaging markers, MRI and PET, plasma biomarkers, and/or cell markers that could support clinicians and researchers in differentiating pseudoprogression…
- Trial name
- NCT06113705
- Testing
- 18F-GE-180 PET, Advanced MRI, Collection of hematopoietic stem cells
- Where
- Italy
- Volunteers
- 75 people
- Sponsor
- Istituto Clinico Humanitas
Glioblastoma, MRI Spectroscopy
Correlative Analysis Between Magnetic Resonance Spectroscopy (MRS) and Essential Clinicobiological Data in Glioblatoma Multiforme (GBM)
Glioblastoma multiforme (GBM) is the most common primary brain tumor, and it is well-known to be associated with a poor prognosis. MRI is the key medical technique for the diagnosis and the follow-up of GBM.
- Conditions
- Glioblastoma, MRI Spectroscopy, Tumor Microenvironment, Biomarkers / Blood
- Trial name
- GLIOMIT (NCT07211841)
- Testing
- MRS study, blood samples
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Solid Tumors, Glioblastoma, Recurrent Malignant Gliomas
Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
The purpose of this study is to determine the safety, tolerability, and the maximum tolerated dose/recommended phase II dose of carboxyamidotriazole orotate (CTO) as a single agent in patients with advanced or metastatic solid…
- Trial name
- NCT01107522
- Testing
- CTO, CTO and Temodar®, CTO, Temodar®, Radiation therapy
- Where
- 4 sites in United States
- Volunteers
- 100 people
- Sponsor
- Tactical Therapeutics, Inc.
Glioma, Glioblastoma
Infigratinib in Recurrent High-Grade Glioma Patients
This trial is an open-label, multicenter, Phase 0 trial that will enroll up to 20 participants with recurrent high-grade glioma with FGFR1 K656E or FGFR3 K650E mutation or FGFR3-TACC3 translocation which are scheduled for…
- Conditions
- Glioma, Glioblastoma, GBM
- Trial name
- NCT04424966
- Testing
- Infigratinib
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- Nader Sanai
Brain Tumor, Brain Tumor, Recurrent
Monteris AutoLITT™ FIM Safety Trial for Recurrent/Progressive Brain Tumors
The main purpose of this study is to evaluate the safety and performance of the AutoLITT system for the treatment of recurrent/progressive glioblastoma multiforme tumors (GBM).
- Conditions
- Brain Tumor, Brain Tumor, Recurrent, Brain Neoplasm, Brain Cancer
- Trial name
- NCT00747253
- Testing
- AutoLITT system
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Monteris Medical
Astrocytoma, Grade III, Glioblastoma
Multi-kinase Inhibitor TG02 (TG02) in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma.
This is a three parallel cohort, open-labeled, non-randomized, multicenter study. All three cohorts will enroll independently.
- Trial name
- STEAM (NCT03224104)
- Testing
- TG02, Radiation Therapy, Temozolomide
- Where
- 10 sites in Austria, France and 3 more
- Volunteers
- 71 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Glioblastoma, Radionecrosis of Brain
FET-PET-Guided Management of Pseudoprogression in Glioblastoma
The goal of this diagnostic randomised clinical trial is to determine, in glioblastoma patients with diagnostic uncertainty between pseudoprogression and tumor progression on follow-up MRI after chemoradiation, the added value of…
- Trial name
- FET-POPPING (NCT06480721)
- Testing
- Clinical management based on the index MRI and an additional [¹⁸F] FET PET scan
- Where
- 8 sites in Netherlands
- Volunteers
- 144 people
- Sponsor
- Veerle Ruijters
Glioblastoma
A Phase 1/2 Study of Safety and Tolerability of MT-125 With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated Glioblastoma
This is a Phase 1, single-arm MT-125 dose escalation study followed by a Phase 2, randomized parallel design dose expansion phase, to determine the safety and tolerability of MT-125 administered 5 consecutive days a week with 2…
- Trial name
- NOVA-GBM (NCT07604285)
- Testing
- MT-125
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Myosin Therapeutics Inc.
Malignant Neoplasms of Brain
Chemotherapy, Radiation Therapy, and Vaccine Therapy With Basiliximab in Treating Patients With Glioblastoma Multiforme That Has Been Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- ZAP IT (NCT00626015)
- Testing
- PEP-3-KLH conjugate vaccine, daclizumab, temozolomide
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- John Sampson
Solid Tumor, Glioblastoma
A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer
This is a first-in-human, open label, multicenter study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and the preliminary antitumor activity of TAS2940 in patients with advanced or metastatic solid…
- Conditions
- Solid Tumor, Glioblastoma, Non-small Cell Lung Cancer, Breast Cancer
- Trial name
- NCT04982926
- Testing
- TAS2940
- Where
- 3 sites in United States, France
- Volunteers
- 29 people
- Sponsor
- Taiho Oncology, Inc.
Advanced Solid Tumors
A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)
This is a multicenter, open-label, Phase 1b/2 study which will be conducted in two parts: a Phase 1b part comprising a dose escalation and an expansion cohort; and a Phase 2 part which will comprise two cohorts.
- Trial name
- NCT01433991
- Testing
- Golvatinib, Lenvatinib
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Eisai Inc.
Brain and Central Nervous System Tumors
Efaproxiral Plus Carmustine in Treating Patients With Progressive or Recurrent Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005855
- Testing
- carmustine, efaproxiral
- Where
- 9 sites in United States
- Volunteers
- 48 people
- Sponsor
- New Approaches to Brain Tumor Therapy Consortium
Glioblastoma Multiforme
NG101m Adjuvant Therapy in Glioblastoma Patients
The purpose of this clinical trial is to evaluate the addition of NG101m adjuvant therapy to standard of care treatment of glioblastoma multiforme.
- Trial name
- NCT04373785
- Testing
- Intensity-modulated radiation therapy, Temozolomide, NG101m
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- NeuGATE Theranostics
Glioblastoma
Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
This phase I trial studies the side effects of nivolumab, BMS-986205, and standard radiation therapy with or without temozolomide in treating patients with new diagnosed glioblastoma.
- Trial name
- NCT04047706
- Testing
- IDO1 Inhibitor BMS-986205 25mg, Nivolumab, Radiation Therapy
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Northwestern University